The Science

What Does The Autoimmune Brain Panel™ Measure?

The Autoimmune Brain Panel™ measures the levels of autoantibodies directed against Dopamine D1 & D2 receptors, Lysoganglioside GM-1 and Tubulin and includes a brain cell stimulation assay.

Autoantibody testing for neuropsychiatric disorders

The Autoimmune Brain Panel™ (also known as the Cunningham Panel™) is a series of five proprietary, validated tests. Four of these tests measure circulating levels of specific autoantibodies in a patient’s serum at the time the specimen is drawn.

The fifth test, the CaMKII assay, measures the ability of a patient’s autoantibodies to stimulate this enzyme, resulting in an upregulation (or increase) of brain neurotransmitters such as dopamine, epinephrine and norepinephrine. This increase can trigger a variety of neurologic and/or psychiatric symptoms.

The Autoimmune Brain™ is a series of five, highly complex metabolic tests

Autoimmune Brain Panel™ Includes 5 Individual Tests

The neuronal targets included in the Autoimmune Brain Panel™ were selected based upon their biological association with specific neurologic and psychiatric symptoms.

Interpreting test results

The Autoimmune Brain Panel™ is considered positive if one or more of these individual test results exceed their normal ranges. The autoantibody test results are expressed as titers (or final dilution) at which an endpoint was observed on an Enzyme-Linked Immunosorbent Assay (ELISA) format. The CaMKII is a cell stimulation assay, which measures the stimulatory ability of a patient’s autoantibody IgGs to increase the activity of the CaMKII enzyme within a human brain cell line. The result is a numeric score that reflects the percent above or below baseline activity.

Identifying autoimmune dysfunction

The Autoimmune Brain Panel™ results can aid a clinician’s diagnosis with supportive laboratory evidence of an autoimmune dysfunction directed against certain biological targets in the brain.

By identifying an underlying autoimmune dysfunction, these results can assist the clinician in selecting an appropriate treatment regimen.

  1. Chain Jennifer L., Alvarez Kathy, Mascaro-Blanco Adita, Reim Sean, Bentley Rebecca, Hommer Rebecca, Grant Paul, Leckman James F., Kawikova Ivana, Williams Kyle, Stoner Julie A., Swedo Susan E., Cunningham Madeleine W. “Autoantibody Biomarkers for Basal Ganglia Encephalitis in Sydenham Chorea and Pediatric Autoimmune Neuropsychiatric Disorder Associated With Streptococcal Infections.” Frontiers In Psychiatry, vol. 11, 2020, p. 564.
  2. Ben-pazi, H., J.A. Stoner, and M.W. Cunningham, Dopamine receptor autoantibodies correlate with symptoms in Sydenham’s chorea. PLoS One, 2013. 8(9): p. e73516
  3. Cunningham, M.W. and C.J. Cox, Autoimmunity against dopamine receptors in neuropsychiatric and movement disorders: a review of Sydenham chorea and beyond. Acta Physiol (Oxf), 2016. 216(1): p. 90-100.
  4. Pukin AV, Jacobs BC, Tio-Gillen AP, Gilbert M, Endtz HP, van Belkum A, Visser GM, Zuilhof H. Detection of antibodies in neuropathy patients by synthetic GM1 mimics. Glycobiology. 2011 Dec;21(12):1642-50.
  5. Yu RK, Usuki S, Ariga T. Ganglioside molecular mimicry and its pathological roles in Guillain-Barré syndrome and related diseases. Infect Immun. 2006;74(12):6517-6527.
  6. Khalili-Shirazi A, Gregson N, Gray I, Rees J, Winer J, Hughes R. Antiganglioside antibodies in Guillain-Barré syndrome after a recent cytomegalovirus infection. J Neurol Neurosurg Psychiatry. 1999 Mar;66(3):376-9.
  7. Kirvan, C. A., Swedo, S.E., Heuser, J.S., Cunningham, M.W. (2003). “Mimicry and autoantibody-mediated neuronal cell signaling in Sydenham chorea.” Nature Medicine 9(7): 914-920.

Learn how the Autoimmune Brain Panel™ can aid in the diagnosis of immune-mediated neuropsychiatric disorders.